Microbiologic contamination of peripheral blood progenitor cells collected for hematopoietic cell transplantation

被引:35
作者
Espinosa, MTF
Fox, R
Creger, RJ
Lazarus, HM
机构
[1] CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,DEPT MED,BONE MARROW PROC LAB,CLEVELAND,OH 44106
[2] CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,DEPT MED,DIV HEMATOL ONCOL,CLEVELAND,OH 44106
[3] CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,IRELAND CANC CTR,CLEVELAND,OH 44106
关键词
D O I
10.1046/j.1537-2995.1996.36996420754.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Peripheral blood progenitor cells (PBPCs) rather than bone marrow are used increasingly to provide hematologic reconstitution when transfused after marrow-ablative chemotherapy. PBPCs often are collected via central venous catheters that have remained in place for long periods of time and that may become infected. Study Design and Methods: The investigators reviewed their 5-year experience in collecting PBPCs for the prevalence of bacterial contamination, Except for cotrimoxazole therapy given to prevent Pneumocystis cariini pneumonia, patients were not given antibiotic prophylaxis. Results: Each patient underwent a median of 7 (range, 2-21) PBPC collections; 0.2 percent (3/1040 collections) were culture positive for bacteria (two collections contained coagulase-negative staphylococci and one contained Serratia marcescens). All culture-positive collections were discarded; no PBPCs were culture positive at the time of thawing and transfusion. Conclusion: This contamination rate is below that previously reported for bone marrow harvests and platelet concentrate collections. Obtaining PBPCs through large-bore central venous catheters has not added to the risk of infection in transplant patients. A program of screening in vitro cultures and strict adherence to sterility techniques can result in very low microbiologic contamination and thus obviates the need for prophylactic antimicrobials in the PBPCs and in the patient.
引用
收藏
页码:789 / 793
页数:5
相关论文
共 49 条
[1]   BLOOD PROGENITOR CELLS - COLLECTION TECHNIQUES AND APPLICATIONS [J].
AHMED, T ;
CIAVARELLA, D ;
COOK, P ;
WUEST, D .
CANCER INVESTIGATION, 1994, 12 (04) :421-424
[2]   A PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH AUTOLOGOUS MARROW SUPPORT IN WOMEN WITH MEASURABLE ADVANCED BREAST-CANCER RESPONDING TO STANDARD-DOSE THERAPY [J].
ANTMAN, K ;
AYASH, L ;
ELIAS, A ;
WHEELER, C ;
HUNT, M ;
EDER, JP ;
TEICHER, BA ;
CRITCHLOW, J ;
BIBBO, J ;
SCHNIPPER, LE ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :102-110
[3]  
AREMAN E M, 1991, Transfusion Medicine Reviews, V5, P214, DOI 10.1016/S0887-7963(91)70210-1
[4]   BONE-MARROW TRANSPLANTATION [J].
ARMITAGE, JO .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) :827-838
[5]   STRATEGIES FOR THE AVOIDANCE OF BACTERIAL-CONTAMINATION OF BLOOD COMPONENTS [J].
BARRETT, BB ;
ANDERSEN, JW ;
ANDERSON, KC .
TRANSFUSION, 1993, 33 (03) :228-233
[6]  
BENSINGER W, 1993, BLOOD, V81, P3158
[7]  
BRICE P, 1992, BONE MARROW TRANSPL, V9, P337
[8]   AUTOLOGOUS BONE-MARROW TRANSPLANT IN ACUTE MYELOID-LEUKEMIA IN 1ST REMISSION [J].
CASSILETH, PA ;
ANDERSEN, J ;
LAZARUS, HM ;
COLVIN, OM ;
BENNETT, JM ;
STADTMAUER, EA ;
KAIZER, H ;
WEINER, RS ;
EDELSTEIN, M ;
OKEN, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :314-319
[9]  
CHADWICK JR, 1995, J HEMATOTHER, V4, P223
[10]   AUTOLOGOUS BONE-MARROW TRANSPLANTATION - CURRENT STATUS AND FUTURE-DIRECTIONS [J].
CHESON, BD ;
LACERNA, L ;
LEYLANDJONES, B ;
SAROSY, G ;
WITTES, RE .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (01) :51-65